Pharma Mar SA ( (PHMMF) ) has released its Q1 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Pharma Mar SA is a biotechnology company specializing in the development and commercialization of innovative oncology and RNA interference therapies. Operating in the pharmaceutical sector, it is recognized for its focus on marine-derived drugs for cancer treatment.
In its latest earnings report for the first quarter of 2025, Pharma Mar SA announced a significant increase in recurring revenue, driven by strong sales and royalties. The company also highlighted strategic partnerships and advancements in its research and development initiatives.
Key financial metrics revealed a 19% rise in recurring revenue, reaching €37.8 million, with net sales up by 22% and royalties increasing by 16%. Despite a decrease in non-recurring revenue, the company’s EBITDA improved by 60%. Strategic moves included a licensing agreement with Merck for Zepzelca in Japan and a substantial grant from the European Commission for RNAi projects.
Pharma Mar’s R&D expenditure decreased by 22%, attributed to the completion of major clinical trials. The company continues to invest in early-stage development, with ongoing trials in oncology and RNA interference. Operating expenses rose due to preparations for new product launches.
Looking ahead, Pharma Mar SA remains focused on expanding its market presence and advancing its clinical pipeline. The management maintains a stable outlook, supported by a strong cash position and ongoing strategic collaborations.